表皮調(diào)節(jié)素(EREG)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Epiregulin (EREG)
EPR; ER; Proepiregulin
- 編號(hào)SEB945Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.156-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.058ng/mL.
- 樣本類型tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2873 ¥ 4104 ¥ 18468 ¥ 34884 ¥ 287280
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)表皮調(diào)節(jié)素(EREG),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測(cè)溶液A100µL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將表皮調(diào)節(jié)素(EREG)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的表皮調(diào)節(jié)素(EREG)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的表皮調(diào)節(jié)素(EREG)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的表皮調(diào)節(jié)素(EREG)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB945Mu01 | 表皮調(diào)節(jié)素(EREG)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB945Mu02 | 表皮調(diào)節(jié)素(EREG)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB945Mu01 | 表皮調(diào)節(jié)素(EREG)多克隆抗體 | WB; IHC; ICC; IP. |
PAB945Mu02 | 表皮調(diào)節(jié)素(EREG)多克隆抗體 | WB; IHC; ICC; IP. |
SEB945Mu | 表皮調(diào)節(jié)素(EREG)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCB945Mu | 表皮調(diào)節(jié)素(EREG)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMB945Mu | 表皮調(diào)節(jié)素(EREG)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
British Journal of Cancer | Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells [Nature: 2012103] |
J Pharmacol Exp Ther. | Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis. [Pubmed: 24309559] |
Molecular Carcinogenesis | The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines [Pubmed:23625689] |
Am J Physiol Gastrointest Liver Physiol. | Epiregulin promotes the emergence and proliferation of adult liver progenitor cells. [Pubmed:24812054] |
European Review for Medical and Pharmacological Sciences | Epiregulin-loaded PLGA nanoparticles increase human keratinocytes proliferation: preliminary data [pubmed:27383296] |
Oncotarget | Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation [PMC5593575] |
American journal of respiratory cell and molecular biology | Potential Involvement of the Epidermal Growth Factor Receptor Ligand Epiregulin and Matrix Metalloproteinase-1 in Pathogenesis of Chronic Rhinosinusitis [pubmed:28398769] |
International?Journal?of?Cancer | Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer [Pubmed: 30252132] |
Epiregulin is released from intervertebral disks and induces spontaneous activity in pain pathways [Doi: 10.1097/PR9.0000000000000718] | |
Cell proliferation | Epiregulin enhances odontoblastic differentiation of dental pulp stem cells via activating MAPK signalling pathway [Pubmed: 31454111] |
International Journal of Molecular Sciences | Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts [Pubmed: 31771279] |
Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
Reprod Sci | Compromised Cumulus-Oocyte Complex Matrix Organization and Expansion in Women with PCOS [34748173] |
Tissue and Cell | MiR-192-5p suppresses M1 macrophage polarization via epiregulin (EREG) downregulation in gouty arthritis [34715618] |